๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Myeloma
Clinical trial register · China

Multiple Myeloma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 44 Guangzhou 29 Shanghai 25 Tianjin 22 Hangzhou 20
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing44 Guangzhou29 Shanghai25 Tianjin22 Hangzhou20
All 57 locations
Target enrolment
to

Multiple Myeloma trials in China

126 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
NCT06429150Multiple Myeloma, Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
NCT03271632Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2026-12-31
Not yet open
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07830485Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
24
Tianjin
2026-10-15
Recruiting
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
NCT07620275Multiple Myeloma
DrugKsvcbd
Chinese PLA General Hospital
Phase 1
9
Beijing, Tianjin
2026-09-03
Not yet open
A Open-Label Phase in Participants With Multiple Myeloma
NCT07764861Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
120
Beijing
2026-08-15
Recruiting
A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
NCT07652281Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
97
Beijing
2026-07-23
Recruiting
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
NCT07409454Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-07-07
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
Hoffmann-La Roche
Phase 3
380
Guangzhou, Nanjing, Qingdao, Kunming, Hangzhou, Jinan, Nanning, Shanghai
2026-06-23
Recruiting
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
NCT07490613Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
99
Suzhou
2026-06-02
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253Multiple Myeloma
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Not yet open
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
260
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Zhanjiang, Nanning
2026-06
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Nanchang, Shenzhen, Tianjin
2026-05-31
Recruiting
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
NCT07255898Multiple Myeloma, Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Chengdu
2026-03-25
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441Multiple Myeloma
Janssen Research & Development, LLC
Phase 2
157
Beijing, Chaoyang District, Guangzhou, Shanghai
2026-02-08
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou
2026-02-04
Not yet open
Isa-VRD in TIE HRMM
NCT07334535Multiple Myeloma
Peking Union Medical College Hospital
Phase 4
117
Beijing
2026-01-30
Recruiting
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
NCT07336823Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
Phase EARLY_PHASE1
9
Foshan
2026-01-20
Recruiting
68Ga-BCMA PET/CT in Multiple Myeloma
NCT07319897Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
Peking University First Hospital
Phase 2/3
300
Beijing, Shijiazhuang, Jilin City
2025-12-25
Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
36
Zhengzhou, Nanjing, Xuzhou, Shanghai, Xiโ€™an
2025-12-10
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Recruiting
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
NCT06514508Multiple Myeloma
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
60
Beijing, Harbin
2025-12-01
Recruiting
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
NCT07497165Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma
Shanxi Bethune Hospital
Observational
48
Taiyuan
2025-11-01
Recruiting
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
NCT07413809Multiple Myeloma
The Affiliated People's Hospital of Ningbo University
Phase 3
92
Ningbo
2025-10-31
Recruiting
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
NCT07489534Multiple Myeloma
Daihong Liu
Phase 2
25
Beijing
2025-09-29
Not yet open
Risk-adapted Therapeutic Strategy in +1q NDMM
NCT07045168Multiple Myeloma
FengYan Jin
Observational
200
Changchun
2025-09-15
Not yet open
Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
NCT06580223Multiple Myeloma, Venous Thromboembolism
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
530
Wuhan
2025-09-01
Not yet open
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
NCT07090954Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2
32
Shanghai, Xi'an
2025-08-31
Recruiting
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
NCT07239323B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
Chongqing Precision Biotech Co., Ltd
Phase 1
24
Kunming
2025-07-01
Active, closed
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
NCT06934044Multiple Myeloma
Hoffmann-La Roche
Phase 1
20
Guangzhou, Tianjin, Nanchang, Wenzhou, Wuhan
2025-05-13
Recruiting
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
NCT06976437B Cell Lymphoma, Multiple Myeloma
YANRU WANG
Phase EARLY_PHASE1
21
Zhenjiang
2025-05-06
Recruiting
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
NCT07032129Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma, Refractory
Essen Biotech
Phase 1/2
60
Beijing
2025-04-29
Recruiting
Universal CAR-T Cell Therapy for MM
NCT07248176Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Bioray Laboratories
Not applicable
6
Shanghai
2025-04-10
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
NCT07249073Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
9
Tianjin
2025-03-28
Recruiting
BCMA CAR-T for Dynamic High-risk Multiple Myeloma
NCT06880393Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2025-03-18
Recruiting
Clinical Study on the Safety and Efficacy of BCMA-CARTยฑASCT in Treating Young Multiple Myeloma Patients
NCT07169500Multiple Myeloma
DrugCar-T
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2025-03-03
Recruiting
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
NCT06793449Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
80
Tianjin
2025-02-05
Recruiting
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
NCT06758713Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy
DrugCar-T
The Third Affiliated Hospital of Southern Medical University
Phase 1
60
Guangzhou
2025-01-15
Recruiting
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
NCT06759181Multiple Myeloma
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2024-12-31
Recruiting
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
NCT06690593Monoclonal Gammopathy of Undetermined Significance (MGUS), Intestinal Flora, Multiple Myeloma, M-Protein
Zhujiang Hospital
Observational
2,990
Guanzhou
2024-12-26
Recruiting
Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
NCT07028970Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Recruiting
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
NCT06732232Relapsed, Refractory, Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1
12
Shanghai
2024-12-12
Recruiting
Risk Stratification and MRD-driven Maintenance for MM After ASCT
NCT06697483Multiple Myeloma
Peking University People's Hospital
Not applicable
100
Beijing, Harbin
2024-12-01
Recruiting
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
NCT06700395Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
136
Shanghai, Chengdu
2024-11-28
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06644118Multiple Myeloma
Zhejiang University
Phase 1
58
Beijing, Xiโ€™an, Hangzhou
2024-10-23
Not yet open
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
NCT06594211Multiple Myeloma
RenJi Hospital
Not applicable
18
Shanghai
2024-10-09
Recruiting
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT06581640Multiple Myeloma, Relapsed/Refractory
The First Affiliated Hospital of Xiamen University
Phase 2
5
Xiamen
2024-09-24
Recruiting
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
NCT06999031Relapsed/Refractory, Multiple Myeloma
The First Affiliated Hospital of Nanchang University
Phase EARLY_PHASE1
12
Nanchang
2024-09-05
Active, closed
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
NCT06566547Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2
116
Hangzhou
2024-08-26
Recruiting
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
NCT06484777Multiple Myeloma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
138
Chengdu
2024-08-07
Recruiting
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
NCT06520176Multiple Myeloma, Hematopoietic Stem Cell Mobilization
The Affiliated People's Hospital of Ningbo University
Phase 3
99
Dongyang, Hangzhou, Huzhou, Jiaxing, Jinhua, Lishui, Ningbo, Shaoxing
2024-08
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Recruiting
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT06409702Newly Diagnosed, High Risk, MRD, Multiple Myeloma
The First Affiliated Hospital of Soochow University
Phase 4
59
Suzhou
2024-06-12
Recruiting
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
NCT06407947Multiple Myeloma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
10
Shanghai
2024-06-06
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Recruiting
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
NCT06539832Multiple Myeloma, MGUS, Gut Microbiota, Infections
Zhujiang Hospital
Observational
300
Guanzhou
2024-05-01
Recruiting
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
NCT06497738Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Observational
112
Changzhou, Nanjing, Nantong, Taizhou, Yancheng
2024-05-01
Recruiting
Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM
NCT06503107Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
60
Wuhan
2024-04-23
Recruiting
The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
NCT06228794Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
458
Wuhan
2024-04-01
Recruiting
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
NCT06385652Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1
30
Beijing
2024-04-01
Recruiting
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06464991Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
240
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
NCT06196255Multiple Myeloma
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2023-12-25
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
AstraZeneca
Phase 1/2
226
Beijing, Changsha, Guangzhou, Shenyang
2023-12-05
Recruiting
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
NCT06463717Multiple Myeloma, Minimal Residual Disease
DrugASCT
First Affiliated Hospital of Zhejiang University
Observational
210
Hangzhou
2023-12-01
Recruiting
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
NCT06158269Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-12
Recruiting
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
NCT06039735Multiple Myeloma
Qilu Hospital of Shandong University
Observational
50
Jinan
2023-11-16
Recruiting
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
NCT06246162Multiple Myeloma
Affiliated Hospital of Nantong University
Phase 1/2
30
Nantong
2023-11-13
Recruiting
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
NCT06132711Multiple Myeloma
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2023-11-10
Recruiting
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
NCT06140966Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2
54
Wuhan
2023-10-20
Recruiting
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06057402Multiple Myeloma
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
Recruiting
A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.
NCT06082284Multiple Myeloma, M Protein
Zhujiang Hospital
Observational
10,000
Guangzhou
2023-10-01
Recruiting
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
NCT06045091Multiple Myeloma, Plasma Cell Leukemia
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1
18
Shanghai
2023-07-04
Recruiting
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
NCT05965115Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Shanghai Zhongshan Hospital
Observational
10,000
Shanghai
2023-07
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
NCT06252792Multiple Myeloma, First Relapse
FengYan Jin
Observational
50
Changchun
2023-06-15
Recruiting
Helical Tomotherapy in Multiple Myeloma
NCT05970198Multiple Myeloma
Fuling Zhou
Not applicable
58
Wuhan
2023-06-14
Active, closed
Study of CT071 Injection in RRMM or PPCL
NCT05838131Multiple Myeloma, Primary Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
20
Shanghai
2023-04-28
Active, closed
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
NCT05850286Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-04-21
Active, closed
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT05860036Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-04-04
Recruiting
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
NCT05686447Monoclonal Gammopathies, Multiple Myeloma, M-protein
Zhujiang Hospital
Observational
200
Guangzhou
2023-01-01
Active, closed
A Study of Daratumumab
NCT05438043Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
213
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou
2022-12-15
Recruiting
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
NCT05521802Multiple Myeloma
Shanghai AbelZeta Ltd.
Phase 1/2
92
Tianjin
2022-11-11
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
European Myeloma Network B.V.
Phase 3
1,594
Beijing, Changchun, Henan, Shandong, Shanghai, Shenyang, Tangshan, Tianjin
2022-09-08
Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NCT05618041Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Not applicable
50
Taiyuan
2022-09-07
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
NCT05299424Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2
48
Beijing
2022-08-09
Recruiting
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
NCT05632380Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2022-07-14
Recruiting
Human BCMA Targeted T Cells Injection๏ผˆBCMA CAR-T๏ผ‰for Subjects With R/R MM
NCT05594797Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase 2
100
Shanghai, Wenzhou
2022-07-12
Recruiting
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
NCT05722405Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Hangzhou
2022-07-01
Rows per page Showing 1–100 of 126
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/condition/multiple-myeloma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 126 of those studies listing the condition Multiple Myeloma.

How many Multiple Myeloma trials are recruiting in China?

91 of the 126 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 12 have not yet opened recruitment, 22 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Multiple Myeloma), 126 studies
PhaseStudiesRecruitingShare
Phase 3301423.8%
Phase 1/2221917.5%
Observational201615.9%
Phase 2161112.7%
Phase 1131110.3%
Phase EARLY_PHASE1131110.3%
Not applicable644.8%
Phase 4544%
Phase 2/3110.8%

Most active sponsors

Lead sponsors with the most studies (Multiple Myeloma)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China129
Janssen Research & Development, LLC95
GlaxoSmithKline62
Pfizer54
AbbVie41
The First Affiliated Hospital of Soochow University43
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology43
Zhujiang Hospital44
Chongqing Precision Biotech Co., Ltd33
FengYan Jin32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.